“With the divestiture of our commercial brands, our strategy and focus now centers on advancing our ifetroban clinical programs,” Kazimi said. As of June 30, Cumberland reported total assets of $63 million, including about $4 million in cash and cash equivalents. The company previously reported positive top-line Phase II results from its FIGHT DMD study, including safety and biomarker findings. The company previously reported positive top-line Phase II results from its FIGHT DMD study, including safety and biomarker findings. About Cumberland Pharmaceuticals (NASDAQ:CPIX)Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products.